178 related articles for article (PubMed ID: 35719366)
21. Identification of the prognostic value of a 2-gene signature of the WNT gene family in UCEC using bioinformatics and real-world data.
Hu Y; Zheng M; Zhang D; Gou R; Liu O; Wang S; Lin B
Cancer Cell Int; 2021 Sep; 21(1):516. PubMed ID: 34565373
[TBL] [Abstract][Full Text] [Related]
22. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
Zhou C; Li C; Yan F; Zheng Y
Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
[TBL] [Abstract][Full Text] [Related]
23. TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification.
Miao L; Chen B; Jing L; Zeng T; Chen Y
Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38305309
[TBL] [Abstract][Full Text] [Related]
24. ZBTB7A, a potential biomarker for prognosis and immune infiltrates, inhibits progression of endometrial cancer based on bioinformatics analysis and experiments.
Geng R; Zheng Y; Zhou D; Li Q; Li R; Guo X
Cancer Cell Int; 2020 Nov; 20(1):542. PubMed ID: 33292231
[TBL] [Abstract][Full Text] [Related]
25. Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis.
Zhang C; Guo C; Li Y; Liu K; Zhao Q; Ouyang L
Front Cell Dev Biol; 2021; 9():726656. PubMed ID: 34409042
[TBL] [Abstract][Full Text] [Related]
26. Elevated Expression of Gamma-Glutamyl Hydrolase Is Associated With Poor Prognosis and Altered Immune Signature in Uterine Corpus Endometrial Carcinoma.
Yu C; Qi H; Zhang Y; Zhao W; Wu G
Front Genet; 2021; 12():764194. PubMed ID: 35082830
[TBL] [Abstract][Full Text] [Related]
27. UBE2C serves as a prognosis biomarker of uterine corpus endometrial carcinoma via promoting tumor migration and invasion.
Ma S; Chen Q; Li X; Fu J; Zhao L
Sci Rep; 2023 Oct; 13(1):16899. PubMed ID: 37803076
[TBL] [Abstract][Full Text] [Related]
28. Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation.
Yuan Y; Chen Z; Cai X; He S; Li D; Zhao W
Front Oncol; 2021; 11():766947. PubMed ID: 34868993
[TBL] [Abstract][Full Text] [Related]
29. CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma.
Xue S; Su XM; Ke LN; Huang YG
Front Oncol; 2023; 13():1077780. PubMed ID: 36845675
[TBL] [Abstract][Full Text] [Related]
30. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
[TBL] [Abstract][Full Text] [Related]
31. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
Front Oncol; 2022; 12():923641. PubMed ID: 35719911
[TBL] [Abstract][Full Text] [Related]
32. The Circadian Gene NPAS2 Act as a Putative Tumor Stimulative Factor for Uterine Corpus Endometrial Carcinoma.
Zheng X; Lv X; Zhu L; Xu K; Shi C; Cui L; Ding H
Cancer Manag Res; 2021; 13():9329-9343. PubMed ID: 34992456
[TBL] [Abstract][Full Text] [Related]
33. High expression of the ferroptosis-associated MGST1 gene in relation to poor outcome and maladjusted immune cell infiltration in uterine corpus endometrial carcinoma.
Yan J; Ye G; Shao Y
J Clin Lab Anal; 2022 Apr; 36(4):e24317. PubMed ID: 35218676
[TBL] [Abstract][Full Text] [Related]
34. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
35. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
36. A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer.
Lei P; Wang H; Yu L; Xu C; Sun H; Lyu Y; Li L; Zhang DL
Int Immunopharmacol; 2022 Jul; 108():108743. PubMed ID: 35413679
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.
Sun Y; Zhang K; Wang T; Zhao S; Gao C; Xue F; Wang Y
Sci Rep; 2024 Mar; 14(1):6134. PubMed ID: 38480789
[TBL] [Abstract][Full Text] [Related]
38. Immune Infiltrates of m5C RNA Methylation-Related LncRNAs in Uterine Corpus Endometrial Carcinoma.
Gu WX; Chen Y; Wang W
J Oncol; 2022; 2022():1531474. PubMed ID: 35392434
[TBL] [Abstract][Full Text] [Related]
39. Human
Rathbun LA; Magliocco AM; Bamezai AK
Oncotarget; 2023 May; 14():426-437. PubMed ID: 37141412
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of
Zheng R; Lai G; Li R; Hao Y; Cai L; Jia J
J Gastrointest Oncol; 2021 Feb; 12(1):153-173. PubMed ID: 33708433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
